Comparing the Expected Benefit of Extra-corporeal-shockwave Therapy (ESWT) Treatment to Standard Care in Treating Diabetic Foot Ulcers

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Information provided by (Responsible Party):
Ofer Elishuv, Hadassah Medical Organization Identifier:
First received: September 4, 2011
Last updated: December 22, 2011
Last verified: August 2011
The purpose of this study is to determine if Extra-corporeal-shockwave Therapy (ESWT) added to standard of care wound therapy significantly improves time to complete wound healing in diabetic foot wounds.

Condition Intervention
Diabetic Foot
Device: shock wave therapy
Device: dermagold shockwave
Procedure: standard of care

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: ESWT Treatment of Diabetic Foot VS. Standard Care Trial

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • healed ulcer [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: January 2012
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: shock wave therapy, shortened wound healing time Device: shock wave therapy
shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
Device: dermagold shockwave
shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
normal wound care
standard of care intervention
Procedure: standard of care
regular care including debridement and bandaging.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed Informed Consent.
  2. Diagnosed with Diabetes.
  3. An Active Diabetic Ulcer larger than 5 cm2
  4. Sufficient limb perfusion.(e.g no compartment syndrome ankle Brachial Index (ABI)>=0.5

Exclusion Criteria:

  1. Pregnancy.
  2. The patient is under another research protocol.
  3. One of the following:

    A. ABI<0.5 C.Significant Arterial-Venous injury. D. Lymphedema.

  4. The patient underwent Chemotherapy or Radiotherapy 60 days or less prior to recruitment date.
  5. Sufficient Noncompliant.
  6. Sickle Cell Anemia, HIV, Immunodeficiency, HgB Anemia, DVT, Chronic Renal Failure, Systemic use of Steroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Ofer Elishuv, Doctor, Hadassah Medical Organization Identifier: NCT01499472     History of Changes
Other Study ID Numbers: ofer02-HMO-CTIL 
Study First Received: September 4, 2011
Last Updated: December 22, 2011
Health Authority: Israel:Ministry of Health - Director General

Additional relevant MeSH terms:
Diabetic Foot
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Diabetic Neuropathies
Endocrine System Diseases
Foot Ulcer
Leg Ulcer
Skin Diseases
Skin Ulcer
Vascular Diseases processed this record on February 11, 2016